Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed CD20+ B-cell non-Hodgkin's lymphoma~  * Relapsed following chemotherapy and eligible for platinum-containing regimen~* Measurable disease~  * Must be at least 1.5 x 1.5 cm~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* ECOG 0-2~Hematopoietic:~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 75,000/mm\^3~Hepatic:~* Bilirubin no greater than 2.0 mg/dL~Renal:~* Creatinine no greater than 1.5 times upper limit of normal~Cardiovascular:~* No uncontrolled hypertension~Other:~* HIV negative~* No other active malignancy~* No uncontrolled diabetes mellitus~* No uncontrolled peptic ulcer disease~* No uncontrolled infection~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rituximab+dexamethasone+cisplatin+cytarabine+sargramostim (Type: EXPERIMENTAL): Patients receive rituximab IV on days 1, 8, 15, and 22 for the first course only. Patients receive dexamethasone orally or IV on days 1-4, cisplatin IV continuously for 24 hours on day 1, cytarabine IV over 3 hours every 12 hours for 2 doses on day 2, and sargramostim (GM-CSF) subcutaneously on days 3-12 or until blood counts recover. Chemotherapy repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 3 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).